Compare ARWR & NYT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARWR | NYT |
|---|---|---|
| Founded | 2003 | 1851 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Newspapers/Magazines |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 11.5B |
| IPO Year | 2009 | 1994 |
| Metric | ARWR | NYT |
|---|---|---|
| Price | $58.19 | $78.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 6 |
| Target Price | ★ $81.50 | $67.33 |
| AVG Volume (30 Days) | 1.9M | ★ 2.4M |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.17% |
| EPS Growth | ★ 99.80 | 18.08 |
| EPS | 0.22 | ★ 2.09 |
| Revenue | $16,142,321.00 | ★ $1,783,639,000.00 |
| Revenue This Year | N/A | $10.40 |
| Revenue Next Year | N/A | $6.35 |
| P/E Ratio | $269.95 | ★ $37.87 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.66 | $44.83 |
| 52 Week High | $76.76 | $82.74 |
| Indicator | ARWR | NYT |
|---|---|---|
| Relative Strength Index (RSI) | 36.19 | 56.46 |
| Support Level | $36.34 | $69.30 |
| Resistance Level | $66.37 | N/A |
| Average True Range (ATR) | 3.00 | 2.10 |
| MACD | -0.49 | -0.09 |
| Stochastic Oscillator | 13.32 | 53.42 |
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as NYTimes and various smartphone applications. The company has two segments: New York Times Group and The Athletic. The company generates the majority of its revenue from the NYTG segment. The NYTG and The Athletic segments derive revenue from subscriptions, Advertising, and others, where the majority source of revenue for both segments is subscription.